Motoi Ohba

4.2k total citations
66 papers, 3.3k citations indexed

About

Motoi Ohba is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Motoi Ohba has authored 66 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Molecular Biology, 13 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Motoi Ohba's work include Protein Kinase Regulation and GTPase Signaling (31 papers), Metabolism, Diabetes, and Cancer (12 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Motoi Ohba is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (31 papers), Metabolism, Diabetes, and Cancer (12 papers) and PI3K/AKT/mTOR signaling in cancer (9 papers). Motoi Ohba collaborates with scholars based in Japan, United States and South Korea. Motoi Ohba's co-authors include Toshio Kuroki, Toshimitsu Yamaoka, Tohru Ohmori, Sojiro Kusumoto, Koichi Andō, Mariko Kashiwagi, Satoru Eguchi, Gerald D. Frank, Keiko Ishino and Tamar Tennenbaum and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and SHILAP Revista de lepidopterología.

In The Last Decade

Motoi Ohba

66 papers receiving 3.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Motoi Ohba Japan	38	2.3k	601	434	421	404	66	3.3k
Fumin Chang United States	17	2.3k 1.0×	964 1.6×	382 0.9×	338 0.8×	213 0.5×	26	3.5k
Diana Mechtcheriakova Austria	31	2.3k 1.0×	439 0.7×	915 2.1×	477 1.1×	362 0.9×	64	3.6k
Quansheng Zhou China	37	2.3k 1.0×	640 1.1×	871 2.0×	366 0.9×	433 1.1×	89	3.7k
Almudena Porrás Spain	27	2.3k 1.0×	694 1.2×	392 0.9×	373 0.9×	688 1.7×	72	3.6k
Fei Chen China	30	1.9k 0.8×	521 0.9×	380 0.9×	373 0.9×	224 0.6×	114	3.3k
Zheng‐Gen Jin United States	22	1.8k 0.8×	303 0.5×	590 1.4×	398 0.9×	378 0.9×	29	2.8k
Kohji Hanasaki Japan	36	2.5k 1.1×	345 0.6×	686 1.6×	579 1.4×	533 1.3×	83	4.0k
Paul Nicklin United Kingdom	23	1.8k 0.8×	391 0.7×	282 0.6×	269 0.6×	311 0.8×	40	3.3k
Louise R. Howe United States	28	2.5k 1.1×	1.1k 1.9×	374 0.9×	301 0.7×	211 0.5×	37	4.4k
Grisha Pirianov United Kingdom	23	2.1k 0.9×	490 0.8×	506 1.2×	615 1.5×	317 0.8×	39	3.2k

Countries citing papers authored by Motoi Ohba

Since Specialization

Citations

This map shows the geographic impact of Motoi Ohba's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Motoi Ohba with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Motoi Ohba more than expected).

Fields of papers citing papers by Motoi Ohba

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Motoi Ohba. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Motoi Ohba. The network helps show where Motoi Ohba may publish in the future.

Co-authorship network of co-authors of Motoi Ohba

This figure shows the co-authorship network connecting the top 25 collaborators of Motoi Ohba. A scholar is included among the top collaborators of Motoi Ohba based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Motoi Ohba. Motoi Ohba is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Yamaoka, Toshimitsu, Motoi Ohba, Ken‐ichi Fujita, et al.. (2018). KRAS and EGFR Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in EGFR. Molecular Cancer Therapeutics. 18(1). 112–126. 39 indexed citations

2.

Yamaoka, Toshimitsu, Tohru Ohmori, Motoi Ohba, et al.. (2017). Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation. Molecular Cancer Research. 15(7). 915–928. 41 indexed citations

3.

Yamaoka, Toshimitsu, Motoi Ohba, Satoru Arata, & Tohru Ohmori. (2017). Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure. Journal of Visualized Experiments. 4 indexed citations

4.

Yamaoka, Toshimitsu, Tohru Ohmori, Motoi Ohba, et al.. (2016). Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation. Molecular Cancer Therapeutics. 15(12). 3040–3054. 28 indexed citations

5.

Park, Jae-Il, Jang‐Soo Chun, Mijin Jeon, et al.. (2007). Activation of protein kinase Cζ mediates luteinizing hormone- or forskolin-induced NGFI-B expression in preovulatory granulosa cells of rat ovary. Molecular and Cellular Endocrinology. 270(1-2). 79–86. 14 indexed citations

6.

Mason, Justin C., et al.. (2004). Decay-accelerating Factor Induction on Vascular Endothelium by Vascular Endothelial Growth Factor (VEGF) Is Mediated via a VEGF Receptor-2 (VEGF-R2)- and Protein Kinase C-α/ϵ (PKCα/ϵ)-dependent Cytoprotective Signaling Pathway and Is Inhibited by Cyclosporin A. Journal of Biological Chemistry. 279(40). 41611–41618. 44 indexed citations

7.

Alt, Addy, Marina Gartsbein, Motoi Ohba, Toshio Kuroki, & Tamar Tennenbaum. (2003). Differential regulation of α6β4 integrin by PKC isoforms in murine skin keratinocytes. Biochemical and Biophysical Research Communications. 314(1). 17–23. 8 indexed citations

8.

Tan, Mingqi, Xuemin Xu, Motoi Ohba, Wataru Ogawa, & Mei‐Zhen Cui. (2003). Thrombin Rapidly Induces Protein Kinase D Phosphorylation, and Protein Kinase C δ Mediates the Activation. Journal of Biological Chemistry. 278(5). 2824–2828. 50 indexed citations

9.

Sumitomo, Makoto, Motoi Ohba, Junichi Asakuma, et al.. (2002). Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. Journal of Clinical Investigation. 109(6). 827–836. 6 indexed citations

10.

Sumitomo, Makoto, Motoi Ohba, Junichi Asakuma, et al.. (2002). Protein kinase Cδ amplifies ceramide formation via mitochondrial signaling in prostate cancer cells. Journal of Clinical Investigation. 109(6). 827–836. 94 indexed citations

11.

Oka, Masahiro, Taro Okada, Shun‐ichi Nakamura, et al.. (2002). Dual regulation of phospholipase D1 by protein kinase C α in vivo. Biochemical and Biophysical Research Communications. 294(5). 1109–1113. 25 indexed citations

12.

García‐Bermejo, Laura, Federico Coluccio Leskow, Teruhiko Fujii, et al.. (2002). Diacylglycerol (DAG)-lactones, a New Class of Protein Kinase C (PKC) Agonists, Induce Apoptosis in LNCaP Prostate Cancer Cells by Selective Activation of PKCα. Journal of Biological Chemistry. 277(1). 645–655. 86 indexed citations

13.

Efimova, Tatiana, Anne Deucher, Toshio Kuroki, Motoi Ohba, & Richard L. Eckert. (2002). Novel Protein Kinase C Isoforms Regulate Human Keratinocyte Differentiation by Activating a p38δ Mitogen-activated Protein Kinase Cascade That Targets CCAAT/Enhancer-binding Protein α. Journal of Biological Chemistry. 277(35). 31753–31760. 75 indexed citations

14.

Han, Jung Min, Yong Kim, Jun Sung Lee, et al.. (2002). Localization of Phospholipase D1 to Caveolin-enriched Membrane via Palmitoylation: Implications for Epidermal Growth Factor Signaling. Molecular Biology of the Cell. 13(11). 3976–3988. 50 indexed citations

15.

Wakino, Shu, Ulrich Kintscher, Zhaowei Liu, et al.. (2001). Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Mitogenic Induction of p21Cip1 by Modulating the Protein Kinase Cδ Pathway in Vascular Smooth Muscle Cells. Journal of Biological Chemistry. 276(50). 47650–47657. 67 indexed citations

16.

Kashiwagi, Mariko, Motoi Ohba, Hiroyuki Watanabe, et al.. (2000). PKCη associates with cyclin E/cdk2/p21 complex, phosphorylates p21 and inhibits cdk2 kinase in keratinocytes. Oncogene. 19(54). 6334–6341. 52 indexed citations

17.

Fujii, Teruhiko, Laura García‐Bermejo, Jorge Caamaño, et al.. (2000). Involvement of Protein Kinase C δ (PKCδ) in Phorbol Ester-induced Apoptosis in LNCaP Prostate Cancer Cells. Journal of Biological Chemistry. 275(11). 7574–7582. 183 indexed citations

18.

Ohba, Motoi, Keiko Ishino, Mariko Kashiwagi, et al.. (1998). Induction of Differentiation in Normal Human Keratinocytes by Adenovirus-Mediated Introduction of the η and δ Isoforms of Protein Kinase C. Molecular and Cellular Biology. 18(9). 5199–5207. 178 indexed citations

19.

Ikuta, Togo, et al.. (1998). Cholesterol Sulfate Activates Transcription of Transglutaminase 1 Gene in Normal Human Keratinocytes. Journal of Investigative Dermatology. 111(6). 1098–1102. 36 indexed citations

20.

Ishino, Keiko, et al.. (1998). Phorbol Ester‐induced G1 Arrest in BALB/MK‐2 Mouse Keratinocytes Is Mediated by δ and η Isoforms of Protein Kinase C. Japanese Journal of Cancer Research. 89(11). 1126–1133. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact